Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, December 1st.

Thank you for your patience.

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY
H

Western blot analysis of extracts from HeLa cells, transfected with either control siRNA (-) or SignalSilence® mTOR siRNA I (+), using mTOR Antibody #2972 and eIF4B Antibody #3592. The mTOR antibody confirms silencing of mTOR expression and eIF4B antibody is used to control for loading and specificity of mTOR siRNA.

Learn more about how we get our images

Fluorescent detection of SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 in living HeLa cells 24 hours post-transfection, demonstrating nearly 100% transfection efficiency.

Learn more about how we get our images
Image

Product Usage Information

CST recommends transfection with 100 nM mTOR siRNA I 48 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.


Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

Product Description

SignalSilence® mTOR siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit mTOR expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.


The mammalian target of rapamycin (mTOR, FRAP, RAFT) is a Ser/Thr protein kinase (1-3) that functions as an ATP and amino acid sensor to balance nutrient availability and cell growth (4,5). When sufficient nutrients are available, mTOR responds to a phosphatidic acid-mediated signal to transmit a positive signal to p70 S6 kinase and participate in the inactivation of the eIF4E inhibitor, 4E-BP1 (6). These events result in the translation of specific mRNA subpopulations. mTOR is phosphorylated at Ser2448 via the PI3 kinase/Akt signaling pathway and autophosphorylated at Ser2481 (7,8). mTOR plays a key role in cell growth and homeostasis and may be abnormally regulated in tumors. For these reasons, mTOR is currently under investigation as a potential target for anti-cancer therapy (9).


siRNA has been used to silence mTOR expression in 293-HEK cells causing decreased raptor expression, decreased p70 S6 kinase phosphorylation, and reduced cell size (9).


1.  Sabers, C.J. et al. (1995) J Biol Chem 270, 815-22.

2.  Brown, E.J. et al. (1994) Nature 369, 756-8.

3.  Sabatini, D.M. et al. (1994) Cell 78, 35-43.

4.  Dennis, P.B. et al. (2001) Science 294, 1102-5.

5.  Gingras, A.C. et al. (2001) Genes Dev. 15, 807-826.

6.  Fang, Y. et al. (2001) Science 294, 1942-5.

7.  Peterson, R.T. et al. (2000) J Biol Chem 275, 7416-23.

8.  Huang, S. and Houghton, P.J. (2003) Curr Opin Pharmacol 3, 371-7.

9.  Navé, B.T. et al. (1999) Biochem J 344 Pt 2, 427-31.

10.  Kim, D.H. et al. (2002) Cell 110, 163-175.


Entrez-Gene Id 2475
Swiss-Prot Acc. P42345


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.